Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hubert Hug

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Drug Discovery Today|February 5, 2003
Anticancer drugs of tomorrow: apoptotic pathways as targets for drug designMarek Los, Christof J Burek, Christopher Stroh, et al.
Drug Discovery Today|November 13, 2004
Ontology-based knowledge management of troglitazone-induced hepatotoxicityHubert Hug, Robert Dannecker, Richard Schindler, et al.
Annals of Nutrition & Metabolism|November 11, 2008
The natural compound ascorbigen modulates NADPH-quinone oxidoreductase (NQO1) mRNA and enzyme activity levels in cultured liver cells and in laboratory ratsAnika E Wagner, Hubert Hug, Richard Gössl, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 3, 2006
Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicineJudy E Anderson, Lise Lotte Hansen, Frank C Mooren, et al.
Molecular Pharmacology|November 4, 2006
Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approachMarco Scarsi, Michael Podvinec, Adrian Roth, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Drug Discovery Today|February 5, 2003
Anticancer drugs of tomorrow: apoptotic pathways as targets for drug designMarek Los, Christof J Burek, Christopher Stroh, et al.
Drug Discovery Today|November 13, 2004
Ontology-based knowledge management of troglitazone-induced hepatotoxicityHubert Hug, Robert Dannecker, Richard Schindler, et al.
Annals of Nutrition & Metabolism|November 11, 2008
The natural compound ascorbigen modulates NADPH-quinone oxidoreductase (NQO1) mRNA and enzyme activity levels in cultured liver cells and in laboratory ratsAnika E Wagner, Hubert Hug, Richard Gössl, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 3, 2006
Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicineJudy E Anderson, Lise Lotte Hansen, Frank C Mooren, et al.
Molecular Pharmacology|November 4, 2006
Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approachMarco Scarsi, Michael Podvinec, Adrian Roth, et al.
Pageof 2